These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26205471)

  • 21. SUMOylation proteins in breast cancer.
    Alshareeda AT; Negm OH; Green AR; Nolan C; Tighe P; Albarakati N; Sultana R; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Apr; 144(3):519-30. PubMed ID: 24584753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with
    Zhu X; Tian T; Ruan M; Rao J; Yang W; Cai X; Sun M; Qin G; Zhao Z; Wu J; Shao Z; Shui R; Hu Z
    J Breast Cancer; 2018 Sep; 21(3):297-305. PubMed ID: 30275858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
    Rodríguez-Pinilla SM; Sarrió D; Honrado E; Moreno-Bueno G; Hardisson D; Calero F; Benítez J; Palacios J
    J Clin Pathol; 2007 Sep; 60(9):1006-12. PubMed ID: 17105822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
    Tilanus-Linthorst MM; Alves C; Seynaeve C; Menke-Pluymers MB; Eggermont AM; Brekelmans CT
    Br J Surg; 2006 Aug; 93(8):961-8. PubMed ID: 16758466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
    Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
    PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct claudin expression characterizes BRCA1-related breast cancer.
    Heerma van Voss MR; van Diest PJ; Smolders YH; Bart J; van der Wall E; van der Groep P
    Histopathology; 2014 Dec; 65(6):814-27. PubMed ID: 25041042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA signatures in hereditary breast cancer.
    Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
    Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
    Hedau S; Batra M; Singh UR; Bharti AC; Ray A; Das BC
    J Cancer Res Ther; 2015; 11(1):158-63. PubMed ID: 25879355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.
    Gonçalves A; Finetti P; Sabatier R; Gilabert M; Adelaide J; Borg JP; Chaffanet M; Viens P; Birnbaum D; Bertucci F
    Breast Cancer Res Treat; 2011 May; 127(1):273-81. PubMed ID: 21069454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
    Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
    Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of BRCA1 expression in sporadic breast carcinomas.
    Lambie H; Miremadi A; Pinder SE; Bell JA; Wencyk P; Paish EC; Macmillan RD; Ellis IO
    J Pathol; 2003 Jun; 200(2):207-13. PubMed ID: 12754741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different methylation and microRNA expression pattern in male and female familial breast cancer.
    Pinto R; Pilato B; Ottini L; Lambo R; Simone G; Paradiso A; Tommasi S
    J Cell Physiol; 2013 Jun; 228(6):1264-9. PubMed ID: 23160909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
    Ignatov T; Eggemann H; Burger E; Fettke F; Costa SD; Ignatov A
    Breast Cancer Res Treat; 2015 Jun; 151(2):357-64. PubMed ID: 25926338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.